Search

everythinglearnresearchcommunity

for

Search:↓

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

The user is experiencing hair thinning and has a vitamin D deficiency, which they suspect might be causing the issue, but they are also considering androgenic alopecia (AGA) as a cause. They are currently using minoxidil and are unable to get finasteride prescribed, while others suggest addressing the vitamin D deficiency and consulting a dermatologist.

The user is experiencing positive results in hair regrowth using a regimen of 0.5 mg dutasteride, 5 mg oral minoxidil, ketoconazole shampoo, microneedling, and a combination of topical minoxidil with RU58841. They report no side effects and express gratitude for the support and inspiration from the community.

A user experienced positive hair regrowth using oral and topical minoxidil, oral dutasteride, microneedling, and supplements. They noted improved hairline and temple density with minor side effects like a few forehead pimples.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

The user has been taking oral finasteride for 2 months, experiencing more hair loss but noticing some fuzzy hair growth on the scalp. They are questioning if this new hair growth is significant.

Oral minoxidil can cause multiple facial hairs to grow from one follicle, known as Pili Multigemini, leading to ingrown hairs and zits. Users report increased facial and body hair growth, with some experiencing fewer issues after switching to dutasteride.

A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.

Topical Minoxidil may cause pericardial effusion. Caution is advised when using Minoxidil, even topically.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conclusion of the conversation is that the user has experienced significant hair regrowth using a combination of medications, including dutasteride, RU58841, and minoxidil. They have not experienced any noticeable side effects and are considering a hair transplant in the future.

Dutasteride and finasteride are not effectively stopping hair loss for some users, despite long-term use. Some are considering or using RU58841, pyrilutamide, and other treatments like microneedling, while also managing seborrheic dermatitis with diet and topical solutions.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

A 34-year-old man experienced hair loss during the COVID-19 pandemic and successfully treated it using minoxidil, reducing shampoo use, and taking fenugreek. He saw significant improvement within a few months and no longer appears bald.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The user recently started topical dutasteride and microneedling, and has been using RU58841 and Minoxidil for 16 months. They are curious if small black dots at their hairline indicate hair regrowth.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

User discusses hair regrowth using RU58841, minoxidil, and dutasteride. Many users praise the progress and ask about the treatments' effectiveness and side effects.

A user is experiencing severe hair loss, diagnosed with seborrheic dermatitis, and is using Ketoconazole and beclomethasone. They are concerned about potential female pattern baldness and are seeking reassurance and advice.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.